Rectal Cancer Stage III Clinical Trial
Official title:
Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients
Verified date | December 2022 |
Source | Goethe University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch&wait (W&W) approach for patients with clinical complete response (cCR). The ACO/ARO/AIO-18.1 study incorporates several novel and innovative aspects to further optimize multimodal rectal cancer treatment, partly established by our preceding CAO/ARO/AIO-04 and CAO/ARO/AIO-12 randomized trials: (1) patient selection is based on strict, quality controlled MRI features of intermediate and high-risk characteristics (and, thus, complementary to our ACO/ARO/AIO-18.2 trial in "low-risk" rectal cancer), (2) the CRT regimens incorporates 5-FU/oxaliplatin with doses and intensities shown to be effective and well-tolerated without compromising treatment compliance in CAO/ARO/AIO-04, (3) the sequence of CRT, CT, and surgery/W&W adopts the TNT approach as established by our CAO/ARO/AIO-12 and OPRA trial, (4) surgical stratification allows for W&W management for strictly selected patients with clinical complete response (cCR). Thus, we hypothesize that TNT with 5-FU/oxaliplatin-CRT followed by consolidation chemotherapy may increase organ preservation while maintaining DFS as compared to RAPIDO-like short-course RT followed by consolidation chemotherapy.
Status | Active, not recruiting |
Enrollment | 702 |
Est. completion date | October 14, 2028 |
Est. primary completion date | October 14, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of rectal adenocarcinoma localised 0 - 12 cm from the anocutaneous line as measured by rigid rectoscopy (i.e. lower and middle third of the rectum) - Staging requirements: High-resolution, thin-sliced (i.e. 3mm) magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure. - MRI-defined inclusion criteria: presence of at least one of the following high-risk conditions: - any cT3 if the distal extent of the tumor is < 6 cm from the anocutaneous line, or - cT3c/d in the middle third of the rectum (= 6-12 cm) with MRI evidence of extramural tumor spread into the mesorectal fat of more than 5 mm (>cT3b), or - cT3 with clear cN+ based on strict MRI-criteria - cT4 tumors, or - Tany middle/low third of rectum with clear MRI criteria for N+ - mrCRM+ (< 1mm), or - Extramural venous invasion (EMVI+) - Trans-rectal endoscopic ultrasound (EUS) is additionally used when MRI is not definitive to exclude early cT1/T2 disease in the lower third of the rectum or early cT3a/b tumors in the middle third of the rectum. - Spiral-CT of the abdomen and chest to exclude distant metastases. - Aged at least 18 years. No upper age limit. - WHO/ECOG Performance Status 0-1 - Adequate haematological, hepatic, renal and metabolic function parameters: - Leukocytes = 3.000/mm^3, ANC = 1.500/mm^3, platelets = 100.000/mm^3, Hb > 9 g/dl - Serum creatinine = 1.5 x upper limit of normal - Bilirubin = 2.0 mg/dl, SGOT-SGPT, and AP = 3 x upper limit of normal • Informed consent of the patient Exclusion Criteria: - Lower border of the tumor localised more than 12 cm from the anocutaneous line as measured by rigid rectoscopy - Distant metastases (to be excluded by CT scan of the thorax and abdomen) - Prior antineoplastic therapy for rectal cancer - Prior radiotherapy of the pelvic region - Major surgery within the last 4 weeks prior to inclusion - Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. - Subject (male or female) is not willing to use highly effective methods of Contraception during treatment and for 6 months after the end of treatment. - On-treatment participation in a clinical study in the period 30 days prior to inclusion - Previous or current drug abuse - Other concomitant antineoplastic therapy - Serious concurrent diseases, including neurologic or psychiatric disorders (incl. dementia and uncontrolled seizures), active, uncontrolled infections, active, disseminated coagulation disorder - Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) < 6 months before enrolment - Prior or concurrent malignancy < 3 years prior to enrolment in study (Exception: non-melanoma Skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is continuously disease-free - Known allergic reactions on study medication - Known dihydropyrimidine dehydrogenase deficiency - Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (these conditions should be discussed with the patient before registration in the trial). |
Country | Name | City | State |
---|---|---|---|
Germany | Clincal Center "St. Marien" Amberg | Amberg | Bavaria |
Germany | Clincal Center Helios Bad Saarrow | Bad Saarow | Brandenburg |
Germany | Clinic Bayreuth GmbH | Bayreuth | Bavaria |
Germany | Clincal Center Helios Berlin Buch | Berlin | |
Germany | Ev. Waldkrankenhaus, Spandau, | Berlin | |
Germany | Helios Klinikum Berlin Emil von Behring | Berlin | |
Germany | Vivantes Clincial Center in Friedrichshain | Berlin | |
Germany | Franziskus Hospital Bielefeld | Bielefeld | North Rhine-Westphalia |
Germany | Klinikum Bielefeld | Bielefeld | |
Germany | Hospital Bochum | Bochum | North Rhine-Westphalia |
Germany | St. Josef Hospital of the catholic clinic Bochum | Bochum | North Rhine Westphalia |
Germany | Clincal Center Chemnitz | Chemnitz | Saxony |
Germany | Clinical Center Coburg | Coburg | Bavaria |
Germany | Clincal Center Darmstadt | Darmstadt | Hessen |
Germany | Onkologische Schwerpunktpraxis | Darmstadt | |
Germany | Clinic Lippe GmbH (Lemgo/Detmold) | Detmold | North Rhine-Westphalia |
Germany | Oncology Practice Dresden | Dresden | Saxony |
Germany | Radiotherapy Practice Dr. A. Schreiber, Dresden | Dresden | Saxony |
Germany | University Clinic Erlangen | Erlangen | Bavaria |
Germany | Clinical Center "Essen Mitte" | Essen | North Rhine-Westphalia |
Germany | University Clinic Essen | Essen | North Rhine-Westphalia |
Germany | Clincal Center Esslingen | Esslingen | Baden-Wuerttemberg |
Germany | Department of Radiooncology | Frankfurt | |
Germany | Clinic North West gGmbH Frankfurt | Frankfurt am Main | Hessen |
Germany | University Clinic Freiburg | Freiburg | Baden-Wuerttemberg |
Germany | Clinic Fulda | Fulda | Hessen |
Germany | Praxis für Hämatologie und Onkologie | Gießen | |
Germany | MVZ Oncological Cooperation Harz | Goslar | Lower Saxony |
Germany | University Clinic Göttingen | Göttingen | Lower Saxony |
Germany | Universitätsklinikum Halle | Halle (Saale) | |
Germany | Hematological-Oncological Practice Dr. Oleg Rubanov, Hameln | Hameln | Lower Saxony |
Germany | Medical Project Hannover | Hannover | Lower Saxony |
Germany | "St. Bernward" Clincal Center Hildesheim | Hildesheim | Lower Saxony |
Germany | Oncology in Medicinum Hildesheim | Hildesheim | Lower Saxony |
Germany | DRK Clincal Centers North Hessen Kassel | Kassel | Hessen |
Germany | Klinikverbund Allgäu | Kempten | Bavaria |
Germany | University Clinic Kiel | Kiel | Schleswig-Holstein |
Germany | Alexianer Krefeld GmbH / Maria Hilf Krankenhaus | Krefeld | |
Germany | Oncology UnterEms, Leer | Leer | Lower Saxony |
Germany | Clinic Sankt Georg gGmbH, Leipzig | Leipzig | Saxony |
Germany | University Clinic Leipzig | Leipzig | Saxony |
Germany | Uniklinik Schleswig Holstein | Luebeck | |
Germany | University Clinic Magdeburg | Magdeburg | Saxony-Anhalt |
Germany | University Clinic Mainz | Mainz | Rhineland-Palantine |
Germany | University Clinic Mannheim | Mannheim | Baden-Wuerttemberg |
Germany | University Clinic Marburg | Marburg | Hessen |
Germany | Clinic Maria Hilf GmbH | Mönchengladbach | North Rhine-Westphalia |
Germany | Clincal Center "Bogenhausen" Munich | München | Bavaria |
Germany | Technical University Clinic Munich | München | Bavaria |
Germany | Technical University Munich | München | Bavaria |
Germany | Clinic Ostlab, Staufenclinic Schwaeb.Gmuend, Mutlangen | Mutlangen | Baden-Wuerttemberg |
Germany | Dietrich Bonhoeffer Klinik | Neubrandenburg | |
Germany | Sana Clinical Center Offenbach | Offenbach | Hessen |
Germany | Pi.Tri-Studien GmbH, Offenburg | Offenburg | Baden-Wuerttemberg |
Germany | Pius Hospital, Oldenburg | Oldenburg | Lower Saxony |
Germany | University Clinic Oldenburg | Oldenburg | Lower Saxony |
Germany | Medius Clincal Center Ostfildern-Ruit | Ostfildern | Baden-Wuerttemberg |
Germany | Brother clinic St. Josef, Paderborn | Paderborn | North Rhine Westphalia |
Germany | St. Vincenz Hospital Paderborn | Paderborn | North Rhine-Westphalia |
Germany | Prosper Hospital Recklinghausen | Recklinghausen | North Rhine-Westphalia |
Germany | Hospital "Barmherzige Brüder" Regensburg | Regensburg | Bavaria |
Germany | University Clinic Regensburg | Regensburg | Bavaria |
Germany | Mathias-Spital, Rheine | Rheine | North Rhine-Westphalia |
Germany | University Clinic Rostock | Rostock | Mecklenburg Western Pomerania |
Germany | CaritasClinic Saarbrücken | Saarbrücken | Saarland |
Germany | Med. Statistik Saarbrücken GgR | Saarbruecken | |
Germany | Clinic Stuttgart | Stuttgart | Baden-Wuerttemberg |
Germany | Clinical Center "Mutterhaus" Trier | Trier | Rhineland-Palatinate |
Germany | University Clinic for Radioncology Tübingen | Tübingen | Baden-Wuerttemberg |
Germany | University Clinic Ulm | Ulm | Baden-Wuerttemberg |
Germany | Schwarzwald-Baar-Kliniken | Villingen-Schwenningen | |
Germany | Clinic Nordoberpfalz AG, Clinic Weiden | Weiden | Bavaria |
Germany | Evangelical Clinic Wesel | Wesel | North Rhine Westphalia |
Germany | Lahn-Dill Clinics Wetzlar | Wetzlar | Hessen |
Germany | Clinic Wolfsburg | Wolfsburg | Lower Saxony |
Germany | University Clinic Würzburg | Würzburg | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Prof. Dr. med. Claus Rödel |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | organ preservation | it is defined as follows: survival with rectum intact, no major surgery, no stoma. Accordingly, the primary endpoint, organ preservation, will not be reached if any of the following occurs: (1) death, (2) any major surgery other than local excision (R0) performed after randomization, during TNT, at re-staging scheduled 22-24 weeks after start of TNT due to clinical non-cCR, or for any locoregional regrowth after initial cCR requiring salvage-TME, (3) any locoregional regrowth not amenable to salvage surgery, or (4) any stoma (non-re-converted protective stoma within 6 months after completion of TNT, or any stoma needed for toxicity or poor function), whichever occurs first. | 3 years | |
Secondary | Disease-free survival | Disease-free survival | 3 years | |
Secondary | Rate of clinical complete response after TNT: | TNT total neoadjuvant therapy | 3 years | |
Secondary | Rate of immediate TME after TNT | TNT total neoadjuvant therapy TME total mesorectal excision | 3 years | |
Secondary | Cumulative incidence of locoregional regrowth after cCR | cCR clinical complete response | 3 years | |
Secondary | Rate of salvage surgery (LE/TME with or APR/stoma) after locoregional regrowth APR/stoma) after locoregional regrowth | LE local Exision; TME: Transanale endoscopic Mikrochirurgie; APR Abdomino perineal Rectum exstirpation | 3 years | |
Secondary | Cumulative incidence of local recurrence after (salvage) surgery surgery | Cumulative incidence of local recurrence after (salvage) surgery | 3 years | |
Secondary | Postoperative complications of (salvage) surgery | Postoperative complications of (salvage) surgery | 3 years | |
Secondary | Rate of sphincter-sparing (salvage) surgery | Rate of sphincter-sparing (salvage) surgery | 3 years | |
Secondary | Pathological TNM-staging | Pathological tumor evaluations;TNM tumor staging | 3 years | |
Secondary | R0 resection rate; negative circumferential resection rate | R0 Removal of the tumor in healthy tissue | 3 years | |
Secondary | Tumor regression grading according to Dworak | pathological response from scale 1-4 poor to very good ascending | 3 years | |
Secondary | Neoadjuvant rectal score | Neoadjuvant rectal score from low to high values means good to poor | 3 years | |
Secondary | Quality of TME according to MERCURY | Tumor response using MRI scale 1-5 from good to poor descending | 3 years | |
Secondary | Acute and late toxicity assessment according to NCI CTCAE V.5.0) CTCAE V.5.0) | CTCAE V.5.0 | 3 Yeears | |
Secondary | Quality of life C30 based on treatment arm and surgical procedures/organ preservation | Quality of life based on EORTC-QLQs-C30 | 3 years | |
Secondary | functional outcome based on treatment arm and surgical procedures/organ preservation | functional outcome based on Wexner score | 3 years | |
Secondary | Quality of life CR29 based on treatment arm and surgical procedures/organ preservation | Quality of life based on EORTC-QLQs-CR29 | 3 years | |
Secondary | Quality of life CPIN 20 based on treatment arm and surgical procedures/organ preservation | Quality of life based on EORTC-QLQs-CPIN20 Quality of life based on EORTC-QLQs-CPIN20 | 3 years | |
Secondary | Cumulative incidence of distant metastases | Cumulative incidence of distant metastases | 3 Years | |
Secondary | Overall survival | Overall survival | 3 years | |
Secondary | Translational / biomarker studies | The translational research program will include proteomics, genomics and immune profile assessment in primary tumor samples as well as peripheral bloods samples (liquid biopsy).
Tumor tissue samples and blood will be collected, processed and stored using protocols. Primary tumor tissue with either fresh tissue or formalin-fixed, paraffin-embedded (FFPE) tissue will be collected at two different time points: i) preoperative biopsy; ii) before/during surgical resection. Peripheral blood samples will be stored at three different time points: i) immediately before initiation of preoperative treatment (day 1); ii) during therapy assessment at week 22-24 and iii) at the time point of the first follow up. |
3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05495308 -
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
|
||
Recruiting |
NCT04598984 -
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
|
||
Completed |
NCT05723965 -
Using Artificial Intelligence to Predict Rectal Cancer Outcomes
|
||
Not yet recruiting |
NCT05830890 -
Sentinel Lymph Node Biopsy in Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT04503694 -
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
|
Phase 2 | |
Completed |
NCT02363374 -
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03561142 -
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
|
Phase 2 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT05148767 -
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
|
Phase 4 | |
Recruiting |
NCT06254521 -
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
|
Phase 2 | |
Completed |
NCT01325649 -
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
|
N/A | |
Recruiting |
NCT04970498 -
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
|
||
Active, not recruiting |
NCT03840239 -
TNT to Increase the Clinical Complete Response Rate for Distal LARC
|
Phase 2 | |
Active, not recruiting |
NCT03391843 -
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
|
Phase 2 |